Spruce Biosciences $SPRB ( ▼ 6.17% ) just skyrocketed almost 2,100% after the FDA granted its drug candidate Breakthrough Therapy designation.
The shares hit a 52-week high, and investors started paying attention.
But should you?
Here's what's actually happening. Spruce is developing a treatment for Sanfilippo Syndrome Type B, an ultra-rare and fatal genetic disease.
The FDA designation means the agency thinks this drug could be a significant improvement over existing treatments. It also means faster review times and more guidance from regulators.
That sounds promising. But let's talk numbers.
The Financial Reality
YTD Revenue: $4.91 million in 2024, down 51% from $10.09 million the previous year
Market Cap: $73.42 million
P/E Ratio: Negative
Those numbers tell a story. Revenue dropped by half. The company isn't profitable. And losses hit $53.04 million in 2024.
But this is a clinical-stage biotech.
They're burning cash to develop drugs, not selling products yet. That's normal for this stage, but it's also risky.
What This Means
Think of biotech investing like backing a horse before the race even starts.
The FDA news is good. It means Spruce's drug has real potential.
But there's a long road between "breakthrough designation" and "approved drug making money."
$SPRB already doubled on this news. Some investors made quick gains. Others bought at the peak and might be underwater already. That's how volatile these small biotechs work.
If you're looking at SPRB, ask yourself: Can I afford to lose this money? Because with a market cap under $75 million and no revenue stream, this is speculation, not investment.
The upside? If the drug gets approved and works well, early investors could see massive returns. The downside? Most drugs fail. Most small biotechs run out of money.
Analysts have a 12-month price target around $131.25, but analyst targets on micro-cap biotechs are notoriously unreliable.
This is a high-risk, high-reward play.
Great news for the company and patients who need this treatment.
But for your portfolio? Only invest what you can genuinely afford to lose.
Disclaimer: This is not financial advice. Do your own research and consult a qualified financial advisor before investing.
